Compare QNRX & MARPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QNRX | MARPS |
|---|---|---|
| Founded | 2018 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 9.2M |
| IPO Year | 2023 | N/A |
| Metric | QNRX | MARPS |
|---|---|---|
| Price | $6.88 | $4.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 944.9K | 5.5K |
| Earning Date | 05-07-2026 | 02-13-2026 |
| Dividend Yield | N/A | ★ 6.95% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $14.39 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.25 | $4.05 |
| 52 Week High | $41.80 | $6.49 |
| Indicator | QNRX | MARPS |
|---|---|---|
| Relative Strength Index (RSI) | 62.38 | 47.98 |
| Support Level | $4.23 | $4.18 |
| Resistance Level | $8.25 | $4.92 |
| Average True Range (ATR) | 0.61 | 0.19 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 57.06 | 50.37 |
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.